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Introduction
Here we report from the Fifth Annual Meeting of the Associ-
ation for Immunotherapy of Cancer (CIMT) that was orga-
nized as a joint meeting together with the Third International
Conference “Strategies for Immune Therapy”. Approxi-
mately 250 participants came together for 3 days in Würz-
burg for this meeting, which started at 12 April 2007,
to learn more and discuss about recent developments in
the  Weld of infectious diseases and cancer immunology.
The meeting encompassed three days with six scientiWc
sessions, guided poster sessions that were based on 62
abstracts and a satellite-workshop that was dedicated to
immunomonitoring. This report will focus on selected
lectures and poster presentations directly related to tumor
therapy.
Development of immunity
B. Kyewski (Heidelberg, Germany) gave a detailed lecture
on the mechanisms by which tolerance against self-antigens
is generated and maintained. Here, the thymus with its
diVerent compartments and cell subpopulations plays the
central role. Especially the medullary thymic epithelial
cells (mTECs) have been shown to express an enormous
array of antigens that were originally thought to be exclu-
sively expressed in peripheral tissues up until some years
ago. The mTECs can be further divided into immature and
mature TECs, which can be distinguished by the diVerential
expression of the CD80 molecule. The CD80high mTECs
constitute the most diVerentiated subset, present the largest
repertoire of MHC-ligands to developing T cells and are
also able to transfer antigens to thymic dendritic cells
(DCs) for cross-presentation. Both the thymic DCs as well
as the mTECSs are short-lived cell populations and as such
make the medulla a highly dynamic compartment in which
T cells continuously encounter a wide spectrum of antigens.
These two cell populations complement each other by dele-
tion of potentially autoreactive T cells (when antigen is pre-
sented by thymic DCs) as well as by the induction of
antigen-speciWc regulatory T cells (when antigen is pre-
sented by mTECs). The pool of genes that are promiscu-
ously expressed in the mTECs represents most, if not all,
peripheral tissues and is estimated to include about 3,000 of
all currently known genes. Two models have been proposed
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to explain the cell-type speciWc pattern of promiscuous
gene expression. (1) The progressive restriction model, in
which immature mTECs mimic gene expression programs
of distinct tissue-speciWc cell lineages and preserve
cell-type speciWc gene regulation, and (2) the alternative
terminal diVerentiation model which proposes that a random
pattern of promiscuous gene expression is an autonomous
property of mature mTECs. Currently available data tend to
support the model of terminal diVerentiation. Elucidating
the mechanisms that balance the induction of tolerance in
the thymus will allow a better understanding and subse-
quently better treatment of autoimmune diseases in the
future. The high relevance of only subtle changes in expres-
sion levels of autoantigens in mTECs were shown for
patients with Myasthenia gravis, in which a single nucleo-
tide polymorphism in the promotor of the -acetylcholin
receptor leads to small changes in the thymic expression
level of this gene; these diVerent expression levels clearly
correlate with the age of disease onset. Next to deleterious
eVects of defective central tolerance in case of autoimmune
diseases, incomplete or leaky tolerance due to diVerences in
antigen expression in the thymus versus tumor cells (e.g.,
glycosylation of the tumor-speciWc MUC1 protein) could
be exploited in cancer immunotherapy.
Further insight into the lymphoid organs that regulate the
development and selection of lymphocytes was provided
by T. Boehm (Freiburg, Germany). DiVerent animal species
have diVerent immune systems and it is now clear that even
arthropods can generate a diversity of antigen receptors via
alternative splicing whereas early agnatha generate variable
lymphocyte receptors based on gene conversion. In higher
vertebrates, T lymphocytes are equipped with highly diverse
T cell receptors (TCRs) that are generated by gene assembly
and VDJ recombination and are able to recognize self and
non-self antigens. As these receptors are generated during
life by somatic recombination they may not be subject to
Darwinian selection, which leads to the risk of generating
receptors that recognize self antigens. Therefore, vertebrates
had to develop a system of quality control to ensure that
autoreactive T cells are deleted during their development.
Interestingly, thymus appearance coincides in the evolution
with the generation of VDJ recombination. It is known that
mice lacking the Foxn1 gene (“nude mice”) do not have a
thymus. When a revertable allele of Foxn1 was introduced
in the genetic background of a nude mouse, a small thymus-
like structure developed from single cells resulting in the
selection of a normal diverse T cell repertoire. Thus, a single
progenitor cell type, so called thymic epithelial stem cells
can give rise to progenitors of the mTECs and cTECs. The
Foxn1 gene can be traced back to the stage of transition of
invertebrates to vertebrates about 500 Mio years ago and is a
paradigmatic example for a situation in which birth of a sin-
gle new gene can give rise to a new organ.
Vaccination against cancer (prophylactic 
and therapeutic)
H. zur Hausen (Heidelberg, Germany) gave a comprehensive
overview on the incidence of microbial infection in cancer
development and the eVort undertaken to develop vaccines.
The mechanisms involved in virus-linked tumorigenesis
are best known, i.e., infection with DNA- or RNA-viruses
such as the papilloma- (e.g., HPV in anogenital carcinomas),
the herpes- (e.g., EBV in B-cell lymphomas), the hepadanae
(e.g., HBV in hepatocellular carcinomas) or the Xaviviridae
(e.g., HCV in hepatocellular carcinomas) families. In the
development of vaccines a breakthrough was obtained with
the development of a prophylactic vaccine against HPV,
which is able to prevent persistent infection with high-risk
HPV types and as a consequence development of anogenital
cancer. By using the L1 capsid protein of HPV type 6,
11, 16 and 18 as a target antigen (Gardasil®, Merck,
which was recently released on the market) an antibody
mediated immune response is elicited to neutralize these
HPV types. A second prophylactic vaccine against HPV 16
and 18 L1 is expected to be approved soon (Cervarix®,
GSK Biologicals).
T. Aebischer (Berlin, Germany) reported on vaccine
development against Helicobacter pylori for controlling
gastric disease and preventing cancer. It is currently
believed that bacterial infection is promoting rather than
igniting the carcinogenesis and that contact with the stem
cells present in the gastric crypts is necessary for this pro-
cess. HP infections are accompanied by an inXammatory
reaction, with production of IL1-beta and TNF-alpha. At
the same time, it blunts the immune eVectors, inhibits
phagocytosis and eVector T cell activation while inducing
CD4+CD25+ regulatory T cell (Treg) recruitment. Mice
vaccinated with live Salmonella expressing the HP-derived
urease antigen were shown to have a reduced bacterial load
in the gastric epithelium and at optimal dosage could be
protected against bacterial challenge. However, the Weld
lacks adequate animal models to study the protection
against HP-induced gastric cancer, since HP is a human-
speciWc pathogen. Several trials have already addressed the
safety and immunogenicity of Salmonella recombinant vec-
tors in humans to seek proof of principle for a human vac-
cine. These studies provided evidence for immunity against
HP infection in human beings which correlated with T cell
activity. As the investigations revealed that strong antibody
responses developing against the carrier were negatively
correlated with T cell responses, Salmonella-based vac-
cines will need much improvement for eYcient protection
in humans.
In addition to the prophylactic vaccines, several col-
leagues also presented therapeutic vaccine approaches dur-
ing the meeting. Y. Paterson (Philadelphia, USA) reports ofCancer Immunol Immunother (2008) 57:135–142 137
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the development of a therapeutic vaccine against HPV. Her
group proposes to use Listeria monocytogenes (Lm) as live
and safe vaccine vectors. In contrast to other bacterial vec-
tors (such as Salmonella), recombinant Listeria induced
both CD4+ and CD8+ speciWc T cells. Moreover, the weak
induction of neutralizing antibodies makes boosting with
Listeria possible. In mice, Lm-LLO-HPV16 E7 (Lovaxin
C®), in which E7 is secreted as fusion protein joined to a
nonhemolytic listeriolysin O (LLO), induces strong CD4+
and CD8+ T cell responses with migratory capacity into
HPV16 expressing TC-1 tumor, whereas a Lm-HPV16 E7
vaccine, not fused to LLO, induces Tregs, does not mature
DCs nor facilitate T cell tumor inWltration. LLO perforates
the phagolysosome so that the fusion protein can exit into
the cytoplasm and enters the antigen processing pathway to
be presented to cytotoxic T cells. Therapeutic vaccination
with the Lm-LLO-E7 construct is able to eliminate tumors
even in mice expressing the E7 as a transgene in the thyroid
gland and in which peripheral tolerance may be expected.
Similarly, vaccination with Lm-LLO-HER2/neu in HER2/
neu mice developing autochthonous HER2/neu tumors
delayed tumor growth. Tumor escape variants occasionally
developed, in which the HER2/neu regions targeted by the
Listeria-based vaccine were mutated. Thus, under immune
pressure, immunoediting of tumor cells occurs through
mutations of targeted tumor antigens. The conclusion from
such experiments is that cancer vaccines should be able to
prevent immune evasion by targeting tumor-indispensable
epitopes and/or multiple antigens. Currently lovaxin C is
being tested in cervical cancer patients.
In the development of therapeutic tumor vaccines
against “self” tumor antigens, various approaches were
undertaken, such as peptide-based vaccination. It is cur-
rently agreed that when minimal cytotoxic T lymphocyte
(CTL) epitopes are used, a T-helper peptide, such as the
universal CD4+ T-help by PADRE, is in addition required
for vaccine eYcacy. Improvements can also be made by the
addition of an adjuvant to the vaccine. However, P. Bross-
art (Tübingen, Germany) showed that the addition of
low dose IL-2 as an adjuvant in a phase I/II trial with renal
cell cancer (RCC) patients s.c. vaccinated with HLA-A2
restricted MUC-1-peptides (preloaded on DCs) and
PADRE did not increase the persistence of CD8+ T cell in
vivo. In a total of 20 treated RCC patients, Wve experienced
various degrees of tumor regression (one complete remis-
sion) and Wve others a stabilization of the progressive dis-
ease. In vitro tests showed the induction of a CD8+ T cell
response against the MUC-1-derived epitopes as well as
against MUC-1+ tumor cell lines. Additionally, a speciWc T
cell reactivity as measured by ELISPOT could be observed
against epitopes not used for vaccination, suggesting that
epitope spreading occurred upon vaccination in some
patients, which may contribute to the clinical beneWt of
vaccination. Since the number of known target T cell epitopes
for RCC is still limited, eVorts are also being made to iden-
tify novel kidney-associated tumor antigens. The Adipophi-
lin and the regulator of G protein signaling 5 (RGS5) are
interesting candidates which are present in a limited num-
ber of normal tissues and overexpressed in the majority of
human RCC. RGS5 is known to be expressed not only by
tumor cells, but also by activated pericytes during tumor
angiogenesis. Targeting and killing RGS5 expressing peri-
cytes could potentially inhibit angiogenesis, thereby result-
ing in tumor growth control or delay. T cell epitopes
derived from these two antigens that are restricted by HLA-
A2 and -A3 have now been identiWed and could be used for
immunotherapy.
Another approach for a therapeutic vaccine is to make
use of DNA encoding the tumor speciWc antigen fused to a
domain that induces CD4+ T-helper cells. C. Ottensmeier
(Southampton, UK) reported on the eYcacy of such a
naked DNA fusion vaccine design. This encodes the CTL
epitope AH1 (which is a H2-L(d) restricted epitope derived
from the endogeneous retroviral gene product gp70
expressed by colon carcinoma CT26) as tumor antigen cou-
pled to domain 1 (pDOM) from fragment C of tetanus toxin
(Fr-C, consisting of domain 1 and domain 2) known to only
induce CD4+ T cells. Since AH1, as most tumor antigens, is
weakly immunogenic, deletion of dominant regions harbor-
ing both murine and human CTL epitopes in Fr-C (i.e.,
domain 2) directs the immune system towards the tumor
antigen, thereby inducing strong CD8+ anti-tumor immu-
nity and long lasting memory in mice. On the base of the
pre-clinical data, the group decided to initiate a Wrst clinical
trial in patients with prostate cancer, which is a slow grow-
ing tumor with prostate speciWc antigen (PSA) levels
detectable in the serum as a measure for tumor progression
or recurrence. The prostate speciWc membrane antigen
(PSMA) is expressed 1,000-fold higher in prostate cancer
than in normal tissue. The transmembrane domain of
PSMA harbors an HLA-A2 restricted CTL epitope. Cur-
rently, the immunogenicity of this PSMA epitope fused
with pDOM delivered i.m. is being studied in HLA-A2+
prostate cancer patients. The study also assesses the eVect
of electroporation as a novel delivery strategy for DNA.
The early data show for the Wrst time in humans that the
potency of the DNA fusion vaccine can be improved
by delivery of the DNA with electroporation and can be
further enhanced after sequential administration. This
improvement included an increased humoral response
against Fr-C and a faster CD4+ T cell response against
pDOM. This route of administration was well tolerated by
the patients. Also a signiWcant increase in humoral response
against pDOM was found, irrespective of pre-existing lev-
els of antibody. The eYcacy of this vaccination approach to
induce CD8 responses and to control tumor progression is138 Cancer Immunol Immunother (2008) 57:135–142
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to be determined with validated immunomonitoring analy-
sis tools.
In the poster session, the use of peptide-based vaccina-
tion was also illustrated by M. Schmitt (Ulm, Germany).
In a phase I/II trial, the immunological responses against
the HLA class I peptide R3, derived from the receptor for
hyaluronic acid mediated motility (RHAMM/CD168), was
determined. RHAMM/CD168 is expressed on tumor cells
of most patients with myeloid malignancies (AML, MDS,
MM and CLL). The R3 peptide was emulsiWed in incom-
plete Freud’s adjuvant (IFA) and given s.c. biweekly for a
total of four times together with GM-CSF. The peptide vac-
cination was well tolerated and in half of the patients a sig-
niWcant increase of functional R3-speciWc eVector CD8+ T
cells was found. In these responders, clinical eYcacy was
also reported with one complete remission, one partial
remission and one haematological improvement. Because
of these promising results, improvement of the vaccine tar-
geting the RHAMM/CD168 as a tumor-speciWc antigen by
exploiting other adjuvants is currently under investigation.
Another poster reported a phase I study by C. Gentilini
(Berlin, Germany) for HLA-A2+ high-risk AML patients
after allogenic stem cell transplantation (HSCT). Biweekly
vaccination with a WT-1 derived HLA-A2 epitope com-
bined with keyhole limpet hemocyanin (KLH) and a daily
dose of GM-CSF resulted in enhancement of the graft ver-
sus leukaemia-eVect (GvL). In Wve of the six vaccinated
patients, the immune responses were monitored in periphe-
ral blood using tetramer analysis and IFN ELISPOT.
Functional CD8+ T cells were measured after vaccination,
however, these responses disappeared 3 months after HSCT.
In conclusion, WT-1 peptide vaccination could induce an
eVective anti-tumor response in patients with high-risk
AML after HSCT. However, the possible enhancement
of graft versus host-eVect (GvH) due to the adjuvants
warrants further clinical observations in a larger number of
patients.
Another important aspect in the Weld of developing
eVective immune therapy is to identify new targets which
clearly mark the tumor and not healthy tissues. A. Wein-
zierl (Tübingen, Germany) showed the so called “Tübingen
approach” (A method that starts from tumor cells itselfs to
identify, select and validate numbers of MHC/HLA class I-
associated peptides derived from tumor-associated anti-
gens) which can be used to identify potential target antigens
not only by looking for mRNA expression but also by
examining the MHC ligandome. E. Derhovanessian (Tüb-
ingen, Germany) described the direct elution of a novel
HLA-B*1402-restricted epitope from the melanoma/mela-
nocyte-speciWc protein, KU-MEL-1 from a melanoma
cell line using aYnity chromatography followed by mass
spectrometric analysis. Additionally, another study by
S. Jarmalavicius (Berlin, Germany) pointed out that protein
modiWcations such as arginine methylation can be used to
diVerentiate peptides expressed in normal versus melanoma
tissue using mass spectrometry.
Inhibition of speciWc immunity
There is an increasing number of reports demonstrating that
powerful mechanisms exist that can inhibit eVective tumor-
speciWc immunity; the key players as well as the underlying
mechanisms of this inhibition are now being elucidated.
H. von Boehmer (Boston, USA) is studying the conversion
of peripheral naïve T cells to antigen-speciWc regulatory
T-cells (Tregs): suboptimal delivery in the absence of costi-
mulation (peptide infusion over a long period of time and at
low concentrations or antigen delivery by minute amounts
of DEC205-peptide fusion antibodies) results in Treg
induction, which would be beneWcial for the treatment of
autoimmune diseases or in organ-transplanted patients. As
a model, skin grafts derived from male mice are fully
accepted in female mice which have been pretreated with
adequate HY-peptide infusion. This correlates with a
decrease in CD4+ and CD8+ anti-HY eVector cells in vivo
and an increase in Foxp3+ T cells after skin graft transplan-
tation. In mice, such long-lived Treg are CD62L+ and
recruited in antigen draining lymph node. Activated murine
Treg are CD103+ and can migrate to inXamed tissues.
Foxp3 competes with AP-1(Jun/Fos) for its binding to
nuclear factor of activated T cells (NFAT), a transcription
factor regulating cytokine gene expression, in particular
interleukin 2, in activated T cells. Treg function is depen-
dent on the DNA binding NFAT-Foxp3 complex and hence
Foxp3 does not induce relevant gene regulation in the
absence of NFAT. In conditions involving suboptimal acti-
vation of T cells, Foxp3 is bound to NFAT. However, full
activation through the TCR and via costimulatory mole-
cules results in replacement of Foxp3 by AP-1. Whether
lack of Treg conversion after costimulation depends on
competition of AP-1 with Foxp3 for NFAT is presently
unknown. Memory T cells, presumably because of high
AP-1 content, cannot be converted into Treg by subimmu-
nogenic antigenic stimulation even though they can be
converted by retroviral Foxp3 transduction. In mice,
subimmunogenic stimulation of T cells by tumor cells can
result in tumor-speciWc Treg generation. Such CD4+ Treg
can inhibit tumor-speciWc CD8+ T cells not only by altering
their proliferation but also by decreasing their cytolytic
activity, a mechanism which is dependent of TGF- signal-
ing in these CD8+ T cells. Suppressed murine CD8+ T cells
do interact with their target cells, produce IFN- and are
fully equipped with cytolytic molecules (granzyme B and
perforin) but do not kill their targets. The suppressed CD8+
T cells exhibit a delay in the exocytosis of their cytolyticCancer Immunol Immunother (2008) 57:135–142 139
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vesicles as evident by the delayed CD107a cell surface
induction. Removal of Treg by antibody treatment can
reverse the suppressed phenotype of CD8+ T cells and
result in tumor rejection. Such observations again empha-
sized the crucial role of Treg in impairing anti-cancer
immunity at various stages of the immune response. Fur-
ther knowledge of Treg cell development and functions is
absolutely essential for the development of an eVective
therapeutic tumor vaccine.
J. Demengeot (Oeiras, Portugal) is studying the inXu-
ence of microbial infection on the development of Tregs.
Treg can obviously exert opposite eVects here, decreasing
inXammation and favoring the survival of infected animals
on one hand, but increasing microbial load on the other. In
fact, Tregs are equipped to respond to inXammatory signals
and they express multiple surface molecules such as che-
mokine receptors, Toll-like receptors (TLRs 2, 4 and 6),
CD25, the common gamma chain of the IL2/IL15 receptor
and CD28. Thus, cross-talk can be established with eVec-
tors of the innate as well as adaptive immunity, through
cell–cell contact or cytokines. In the NOD mouse model,
where the animals spontaneously develop type I diabetes,
the incidence of disease can be signiWcantly decreased
when small doses of LPS are administered weekly. This
correlates with a signiWcant increase in CD4+ Foxp3+ Tregs
in the spleen. Moreover, protection is transmitted by trans-
fer of the splenocytes of LPS-treated mice, but is abrogated
if the splenocytes have been depleted from CD25+ cells. In
another model of autoimmune disease, RAG-1 deWcient,
TCR-transgenic (T/R-) mice that express exclusively
myelin basic protein (MBP)-speciWc T cells, spontaneously
develop experimental autoimmune encephalomyelitis (EAE),
whereas RAG-1-competent transgenic animals (T/R+)
remain healthy since they are protected by CD4+ T cells
(Treg) expressing endogenous TCRs. These T/R+ mice
can be protected from EAE by immunization with the
MBP-derived peptide that is recognized by the transgenic
TCR when delivered in Complete Freund Adjuvant (CFA)
and this is correlated here again with an expansion of CD4+
Foxp3+ T cells. Adoptive transfer of these CD4+ CD25+
TCR transgenic T cells from T/R+ donors to T/R-mice also
prevented these mice from developing EAE. The observa-
tion that CFA and IFA, but not Alum, induces Treg devel-
opment is intriguing and might have important and direct
implications on the design of future anti-tumor vaccination
approaches.
S.H. van der Burg (Leiden, The Netherlands) and his
group investigates the role of regulatory T cells in HPV16-
induced cervical cancer. In about 60% of healthy individu-
als, circulating T cells were found that are able to secrete
IFN- and IL-5, to proliferate upon antigen-contact and to
migrate to the epithelia of the skin following an intra-der-
mal challenge with peptides coded for HPV type 16 E2, E6
and E7. In contrast to most healthy persons, patients with
pre-malignant high-grade cervical intraepithelial neoplasia
(CIN) and cervical cancer patients fail to mount a speciWc
immune response or displayed an impaired response
against the early antigens of HPV16. Moreover, the lesions
of these patients were strongly inWltrated by CD4+ Foxp3+
regulatory T cells. Interestingly, a proportion of these regu-
latory T cells were shown to be HPV-speciWc and able to
suppress the function of naïve and eVector CD4+ T cells
when stimulated with their cognate HPV-antigens. The
impact of such a type of pre-existing HPV-speciWc immune
responses were discussed in relation to vaccine strategies
and pointed out that therapeutic vaccines may also boost
unwanted immune responses.
Although T regs are the focus of much attention, it is
also clear that other immune cell players are involved in
inhibiting tumor speciWc immunity. V. Bronte (Padua,
Italy) gave an overview on the relevance and function of
myeloid derived suppressor cells (“MDSC”) in mice and
humans. Mouse MDSC co-express CD11b and Gr1 and can
normally be found in the bone marrow of mice, whereas in
the peripheral blood or the spleen they can only be detected
in very low numbers. Nevertheless, their number in the
periphery can increase in tumor-bearing mice and in states
of chronic infection. Recent experiments have shown that
the immune suppression found in mice bearing diVerent
carcinomas clearly depends on the presence of Gr1+
CD11b+ cells inside the tumors. In a model of colon cancer
it could be found that the number of circulating Gr1+
CD11b+ cells signiWcantly increases in the peripheral blood
(up to 11.6%) in mice bearing CT26 tumors that were engi-
neered to secrete GM-CSF. In contrast to CD11b+ cells
from naïve mice, the CD11b+ cells from these tumor-bear-
ing animals could completely suppress alloreactive CD8+ T
cells. MDSCs induce suppression of T cell function by two
L-arginine modifying enzymes, the IFN inducible nitric
oxide synthase 2 (NOS2) and the IL4/IL13 inducible argi-
nase (ARG), respectively. The two enzymes can be acti-
vated independently, but only together do they engage a
complex transcription program that results in suppression
and apoptosis of T cells. In the tumor tissues from prostate
carcinoma patients, ARG and NOS2 double-positive cancer
cells can be found. When tumors were cultured for several
days under conditions that allow maintenance of the tumor
micro-environment, it was possible to detect fully equipped
memory T cells that did not respond to activating stimuli
such as PHA. A combination of ARG and NOS2-inhibitors
could restore their function. As the systemic use of these
inhibitors in patients is prohibited by their toxicity, the
search for small molecular inhibitors has now begun and
promises the development of a new category of drugs with
anti-tumor eVects. MDSCs form a heterogenic population
of cells and this explains the need to identify speciWc140 Cancer Immunol Immunother (2008) 57:135–142
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markers to distinguish diVerent subtypes of MDSCs. In
gene expression arrays of CD11b+ cells from tumor-free
and tumor-bearing mice, IL4R was found to be a potential
marker in distinguishing MDSC sub-populations, as an
IL4R+ cell population up-regulates NOS2 and ARG and
shows suppressive function in spleens of mice with diVer-
ent tumor types. First data from patients with RCC also
suggests that IL4R+ could represent a speciWc marker for
tumor-induced MDSCs in humans. More and better mark-
ers for deWning and monitoring MDSC sub-populations in
patients will have to be identiWed.
Antibodies (eVector mechanisms, new targets, therapy)
Until now the antibodies are the most successful immune
therapeutics in cancer and several talks and posters focused
on the eVector-mechanisms involved, new methods to rap-
idly generate novel antibodies with favorable properties
and the clinical use of new multivalent antibody-based con-
structs. J. Ravetch (New York, USA) demonstrated the
therapeutic eYcacy of IgG antibodies (such as anti-CD20
antibody in the treatment of lymphoma and adult T cell leu-
kemia). IgG can bind (1) to neonatal FcR (FcRN), which
increases the t1/2 of IgG by protecting it from catabolism in
the cell and recycle it to the cell surface back into circula-
tion; (2) to complement (classical or alternative comple-
ment pathway) resulting in cell killing and (3) to Fc-gamma
receptor (FcR), thereby initiating ADCC by NK cells and
inducing inXammation. This latter occurs when the FcR is
an activating receptor (type I or III). However, activation of
the inhibitory FcR (type II) can lead to peripheral toler-
ance and autoimmunity. The aYnity of the IgG isotypes
diVers for the various FcRs; in mice the IgG2a has the high-
est aYnity for activating FcRs. Thus, the balance between
the activating (A) and inhibitory (I) FcR-mediated activity
is important for therapeutic antibodies. To improve this bal-
ance, modiWcations were made at site Asn297 of the IgG.
Fucosylation increased the A/I ratio resulting in an increase
of antibody mediated cytotoxicity (i.e., ADCC) of the
FcR-expressing cells, cells whereas sialylation reduced
this cytotoxic eVect. Currently it is being investigated
whether blocking of the FcR-II, in addition to these modi-
Wcations, might increase the eYcacy of the IgG vaccine.
Additionally, the eYcacy of Ab treatment can be
explained by FcR polymorphisms. This is the case for CD20
Ab-based therapies which signals through the FcRIII
(CD16) receptor as reported by G. Weiner (Iowa City, USA).
ModiWcations in the constant region of CD20 Ab enhance
activation of NK cells and increase ADCC. In separate stud-
ies, Wxation of complement, which is known to induce lysis
of target cells in some conditions, can paradoxically block
activation of NK cells. The concentration of mAb that acti-
vates NK cells is lower than the concentration that Wxes com-
plement. Thus, it may be possible to identify a dose of mAb
that mediates ADCC but is low enough to prevent Wxation of
complement. In summary, for clinical applications, the poly-
morphism of the FcR, the dose of Ab and the activation of
complement proteins are important issues that need to be
considered for improving current clinical beneWt.
D. Neri (Zürich, Switzerland) identiWed Ab-targets from
the vascular system Wrst by biotinylation of vascular cell
surface proteins and then by Wshing out these proteins on a
column followed by 2D peptide mapping. This is a high
throughput system for identiWcation of novel target anti-
gens. Antibodies against these target antigens can then be
raised in the delay of one week (Philochem innovating
chemistry). When the Ab L19 was fused to bioactive mole-
cules such as IL-2 or TNF for targeting the vascularization
speciWcally in tumor tissue, the therapeutic eYcacy of the
Ab in murine models was improved. Currently, a DNA
encoded chemical library, in addition to the phage display
library often used, is under development.
M. Sproll (Martinsried, Germany) presented another
technology platform developed by Morphosys for high
throughput selection and editing of human antibodies. It
consists of a synthetic phage display library of more than
1010 Fab fragments (HuCAL®, GOLD) for rapid selection
of binders against target antigens. An increase in Ab aYnity
(up to 3,000-fold) can then be obtained by diversifying the
complementary determining regions (CDR) of the heavy
and light chains against those from a CDR-library. Several
products are being tested in animal models or in phase I/II
clinical trials covering diVerent research areas such as
tumor therapy or Alzheimer disease.
Another form of antibody-construct for anti-tumor ther-
apy was discussed by M. Penichet (Los Angeles, USA).
Antibody fusion proteins are composed of the cytokines
IL-2, IL-12, or GM-CSF genetically fused to a humanized
IgG3 speciWc for the human HER2/neu. Overexpression of
HER2/neu has been described in several malignancies such
as breast and ovarian cancer and this overexpression is
associated with poor prognosis. The main goal of this
approach is to target suYcient quantities of the immuno-
stimulatory cytokines to the site of HER2/neu expressing
tumors to enhance the tumoricidal activity of the antibody
and/or to elicit a tumor speciWc immune response. Human
IgG3 was chosen because of its extended hinge region,
which provides spacing and Xexibility thereby facilitating
simultaneous antigen and receptor binding. IgG3 is also
very eVective in ADCC and complement activation. These
novel antibody fusion proteins [anti-HER2/neu IgG3-
(human IL-2, also functional in mice), anti-HER2/neu
IgG3-(murine IL-12), and anti-HER2/neu IgG3-(murine
GM-CSF)], expressed in murine myeloma cells, are properly
assembled, secreted, bind antigen and carry out cytokineCancer Immunol Immunother (2008) 57:135–142 141
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and antibody-related activities. Importantly, treatment of
mice bearing human HER2/neu expressing tumors with
these antibody fusion proteins, both as direct anti-tumor
agents and as adjuvant of HER2/neu protein vaccination,
results in signiWcant anti-tumor activity under conditions
in which the antibody alone fails to confer protection.
Physical association between the antigen and the antibody
fusion proteins is required to elicit the most eVective pro-
tection, which involves humoral and cellular immune
responses. In addition, long-term survivors are immune
after challenge with non-HER2/neu expressing variants of
the tumor cells, which might be due to epitope spreading.
The low immunogenicity of the extracellular domain of
HER2/neu (ECDHER2) is due to the fact that although this
molecule is readily internalized by dendritic cells, it is
poorly processed due to its high level of glycosylation that
results in early endosomal retention and recycling to the
cell surface. However, anti-HER2/neu antibody-cytokine
fusion proteins such as IgG3-(IL-2) redirect the traYcking
of ECDHER2 to antigen processing compartments of den-
dritic cells resulting in eVective antigen presentation.
Currently, tri-functional antibodies are being studied in
clinical trials. As showed on two posters, both T. Leidig
(Mainz, Germany) and B. Rodday (Mainz, Germany) used
tri-functional antibodies (catumaxomab and ertumaxomab,
Fresenius Biotech and TRION Pharma) to create the hypo-
thetical tri-cell-complex consisting of a tumor cell (via
EpCAM or HER-2/neu binding), T cell (via CD3 binding)
and accessory cell (via CD16 or CD64 binding through FcR
on NK, DC and macrophages) with the aim of inducing an
eVective anti-tumor response. Both groups analyzed PBMCs
inWltrating the 3D tumor model called multicellular tumor
spheroids and are focusing on the expression of cytokines and
activation markers using ELISA or RT-PCR as readout
system. Both studies concluded that catumaxomab caused
a signiWcant reduction of spheroid volume growth in a
concentration-dependent fashion in vitro due to an increased
incidence of tumor cell apoptosis caused by inWltrated leuko-
cytes. Moreover, the leukocyte inWltration was dependent on
the Ab concentration. These data support the eVective usage
of catumaxomab for immune therapy of patients with malig-
nant ascites as recently shown in a phase II/III study. As
malignant ascitis (containing the three above mentioned cell
types to be targeted by the tri-functional antibody) is associ-
ated with poor prognosis it is very important to decrease the
volume growth of the ascitis and maybe thereby be of clinical
beneWt for such patients (i.e., increased survival time).
Extra-session immunomonitoring
The Third Annual Meeting of the Participants of the CIMT
Immunomonitoring Panel was held following the oYcial
end of the scientiWc program of CIMT 2007. This working
group regroups 24 labs from nine diVerent European
countries and is dedicated to the standardization of
assays applied for immunomonitoring. A satellite-session
on immunomonitoring techniques was organized, with invited
speakers presenting recent developments in the Weld.
A. Thiel (Berlin, Germany) is an expert in detecting antigen-
speciWc T cells by making use of the fast and transient up-
regulation of CD154 (CD40L) on the surface of CD4+ T
cells upon antigen-contact. This assay, that has recently
been published by this group, can be used for the detection
of antigen-speciWc CD4+ T cells independent of cytokine
production. Moreover, also combination with intracellular
cytokine staining is possible. The simplest way of using the
CD154-marker consists of a three color staining combining
CD4 Ab and one deWned cytokine of choice, but more com-
plex experimental settings are feasible with combination of
multiple colors conjugated to surface-markers and diVerent
cytokines allowing the simultaneous detection of complex
populations of antigen-speciWc T cells of diVerent pheno-
types and functionalities.
H.M. Diepolder (Munich, Germany) showed that HLA
class II-tetramers can be successfully used to systematically
screen antigen-speciWc CD4+ T cells in patients with Hepa-
titis C. As the MHC class II-tetramers are currently only
available for a limited number of MHC class II alleles
(mainly DR alleles) there is an urgent need for further
development from companies that could make these
reagents available and aVordable for the scientiWc commu-
nity. The combination of MHC class II-multimer staining
with a subsequent enrichment step with anti-PE magnetic
beads now also allows the detection of peripheral T cells
present at frequencies which are below the currently estab-
lished thresholds of detection. Once such a method has
been extensively validated with dilution of antigen-speciWc
T cell populations, it will be very useful for detecting
tumor-speciWc CD4+ T cells which can only be found in
low numbers in patient material.
C.M. Britten (Leiden, The Netherlands) presented the
results from two consecutive phases of an inter-laboratory
testing project initiated by the CIMT monitoring panel. A
total of 13 centres from six European countries participated
in the study. The results of a Wrst testing round revealed that
the total number of cells analyzed was the most important
determinant for the sensitive detection of antigen-speciWc
CD8+ T cells by tetramer staining. Analysis by ELISPOT
was inXuenced by a combination of cell number and a rest-
ing phase after thawing of PBMCs. The experiments were
repeated in a second phase but now the participants were
asked to change their protocols according to the new guide-
lines distilled from the results of the Wrst phase. The recom-
mendations both improved the number of antigen-speciWc
T cell responses that could be detected in participating labs142 Cancer Immunol Immunother (2008) 57:135–142
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and decreased the variability between the laboratories. Such
“two-step” inter-laboratory projects could deWne rational
bases for immunomonitoring accepted international guide-
lines.
Conclusion
In this meeting we learned about the development of immu-
nity in the thymus, a Weld that needs to be explored in
more detail to understand and overcome tolerance against
tumors. The development of both prophylactic and thera-
peutic vaccines against cancer was extensively discussed.
Several approached were shown; i.e., peptides, viral or bac-
terial vectors for the antigen, DNA (fused to toxin) and
antibodies. For determining the eYcacy of anti-cancer vac-
cines sophisticated and complex immunomonitoring is
required and should be standardized in order to compare
results of clinical trials. Finally it was made clear that the
inhibition of (vaccine-induced) immunity by for instance
regulatory T cells or myeloid suppressor cells should be
deWnitively considered in anti-tumor treatments. In short,
it was again a very pleasant and stimulating meeting. The
authors are looking forward to hear how the Weld continues
to develop next year at CIMT 2008, which will take place
in Mainz, 15¡16 May.